Prof.DaisukeInoue Japan

Prof.DaisukeInoue
Daisuke Inoue, MD/PhD, is Professor of the Third Department of Medicine and Hospital Director at Teikyo University Chiba Medical Center. He graduated from Tokyo University in 1988. In 1993 he joined the Department of Cell Biology&Orthopaedics at Yale University as Postdoctoral Associate. He returned to Japan in 1997 to work at Tokushima University and became Lecturer in 2004. He moved to Teikyo University in 2006 and became Professor in the Division of Endocrinology and Metabolism in 2013. He has also been serving as Director of Teikyo University Chiba Medical Center since 2022. He is an Associate Editor of Journal of Bone and Mineral Metabolism, Endocrine Journal, and Osteoporosis&Sarcopenia, and an Editorial Board Member of BONE and JCEM-Case Reports. His research interests lie in the area of bone biology with specific interest in endocrinological aspects of bone disease and systemic abnormalities associated with osteoporosis including cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), diabetes and aging.

21 MARCH

Time Session
08:30
10:00
[Symposium] Osteoporosis
Osteoporosis and Bone Health
  • New Concept in Osteoporosis Management
    Daisuke InoueJapan Speaker New Concept in Osteoporosis Management- Japnaese Perspectives Operational definition of osteoporosis by WHO is currently "a BMD value -2.5SD or more below the young adult mean", which has been used worldwide for twenty years. WHO has recently initiated a process to revisit this definition as it is not sensitive enough to identify individuals at high risk of fracture, leading to unsatisfactory treatment of patients. Importantly, a history of fracture, particularly within the past two years (termed imminent fracture risk) has been shown to significantly contribute to the risk of subsequent fractures. Regarding a surrogate for evaluating the clinical efficacy of anti-osteoporotic drugs, a proposal from the FNIH-ASBMR-SABRE project has been submitted to the Food and Drug Administration (FDA). This proposal suggests that treatment-related increases in total hip BMD (TH-BMD) at two years could serve as a surrogate endpoint for fracture risk reduction in clinical trials. This is primarily based on the negative correlation observed between increases in total hip BMD and decreases in the incidence of hip fracture in various clinical trials of anti-osteoporotic drugs demonstrated by a meta-regression analysis. The significant role of BMD as a surrogate, along with availability of bone anabolic agents that can greatly increase BMD for a short period of time, has led to the concept of "Goal-directed treatment" of osteoporosis. Accordingly, "anabolic first" sequential therapy is recommended for individuals at high risk of fractures. In Japan, new Guidelines for Prevention and Treatment of Osteoporosis were issued on August 1, 2025. Recent trends in osteoporosis management, as described above, will be discussed in the context of these Japanese guidelines.
  • Bone Fragility in Diabetes
    David LuiHong Kong, China Speaker Bone Fragility in Diabetes
  • Metabolic Bone Disorder in Thalassemia
    Wen-Pin YangTaiwan Speaker Metabolic Bone Disorder in Thalassemia
201AF